骨髓间充质干细胞来源细胞外囊泡治疗COVID-19呼吸衰竭的随机安慰剂对照剂量试验
该2期多中心双盲随机安慰剂对照剂量试验纳入102例COVID-19相关中重度ARDS患者,比较安慰剂、10 mL和15 mL ExoFlo(第1、4天输注)的安全性和疗效。主要终点60天全因死亡率在意向治疗人群中未显著降低(P=.1343),但事后亚组分析中15 mL ExoFlo使60天死亡率降低(RR 0.385,95%CI 0.159-0.931,P=.0340,n=50),且18-65岁患者无通气天数改善(P=.0455,n=50)。15 mL ExoFlo在重度和危重COVID-19相关呼吸衰竭患者中安全性良好。
要点
- 15 mL ExoFlo在COVID-19相关中重度ARDS患者中安全性良好,未报告治疗相关不良事件。
- 意向治疗人群60天死亡率未显著降低(P=.1343),但事后亚组分析显示15 mL剂量组死亡率降低。
- 18-65岁患者接受15 mL ExoFlo后无通气天数改善(P=.0455)。
核心结论
- 15 mL ExoFlo在重度和危重COVID-19相关呼吸衰竭患者中安全性良好。
- 意向治疗人群60天死亡率未显著降低,但事后亚组分析中18-65岁患者死亡率降低且无通气天数改善。
研究设计与样本
- 前瞻性2期多中心双盲随机安慰剂对照剂量试验,在美国五个中心开展。
- 纳入102例COVID-19相关中重度ARDS患者,随机接受安慰剂、10 mL ExoFlo或15 mL ExoFlo,第1天和第4天输注。
- 主要终点为60天全因死亡率,次要终点包括至死亡时间、治疗中出现严重不良事件发生率、7/30/60天出院比例、至出院时间和无通气天数。
主要发现
- 未报告治疗相关不良事件。
- 意向治疗人群60天死亡率在15 mL ExoFlo组较安慰剂组降低但未达统计学显著性(χ2,P=.1343)。
- 事后亚组分析中,15 mL ExoFlo组60天死亡率较安慰剂组降低(相对风险0.385;95%CI 0.159-0.931;P=.0340;n=50)。
- 18-65岁中重度ARDS患者接受15 mL ExoFlo的相对风险为0.423(95%CI 0.173-1.032;P=.0588;n=24)。
- 18-65岁所有参与者接受15 mL ExoFlo后无通气天数改善(P=.0455;n=50)。
关键数值与推荐
- 15 mL ExoFlo与85 mL生理盐水混合后输注。
- 主要终点60天全因死亡率在意向治疗人群未显著降低(P=.1343)。
- 事后亚组分析中15 mL ExoFlo组60天死亡率相对风险0.385(95%CI 0.159-0.931;P=.0340;n=50)。
临床怎么用
- 15 mL ExoFlo剂量在重度和危重COVID-19相关呼吸衰竭患者中显示安全性良好。
- 事后亚组分析提示18-65岁患者可能从15 mL ExoFlo治疗中获得60天死亡率降低和无通气天数改善的获益。
局限性
- 主要终点在意向治疗人群中未达到统计学显著性。
- 死亡率降低和无通气天数改善的结果来自事后亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone marrow mesenchymal stem cell (BM-MSC)-derived extracellular vesicles (ExoFlo) convey the immunomodulatory and regenerative properties of intact BM-MSCs. This study aimed to determine the safety and efficacy of ExoFlo as treatment for moderate to severe ARDS in patients with severe COVID-19. RESEARCH QUESTION: Do two doses of ExoFlo safely reduce mortality in COVID-19-associated moderate to severe ARDS compared with placebo? STUDY DESIGN AND METHODS: A prospective phase 2 multicenter double-anonymized randomized placebo-controlled dosing trial was conducted at five sites across the United States with infusions of placebo, 10 mL of ExoFlo, or 15 mL of ExoFlo on days 1 and 4. Patients (N = 102) with COVID-19-associated moderate to severe ARDS were enrolled and randomized to treatment. Adverse events were documented throughout the study. The primary outcome measure was all-cause 60-day mortality rate. Secondary outcomes included time to death (overall mortality); the incidence of treatment-emergent serious adverse events; proportion of discharged patients at 7, 30, and 60 days; time to hospital discharge; and ventilation-free days. RESULTS: No treatment-related adverse events were reported. Mortality (60-day) in the intention-to-treat population was reduced with 15 mL ExoFlo mixed with 85 mL normal saline (ExoFlo-15) compared with placebo (not significant, χ2, P = .1343). For the post hoc subgroup analyses, 60-day mortality was decreased with ExoFlo-15 compared with placebo (relative risk, 0.385; 95% CI, 0.159-0.931; P = .0340; n = 50). With ExoFlo-15, a relative risk of 0.423 (95% CI, 0.173-1.032; P = .0588; n = 24) was determined for participants aged 18 to 65 years with moderate to severe ARDS. Ventilation-free days improved with ExoFlo-15 (P = .0455; n = 50) for all participants aged 18 to 65 years. INTERPRETATION: The 15 mL dose of ExoFlo was found to be safe in patients with severe or critical COVID-19-associated respiratory failure. In participants aged 18 to 65 years, the risk reduction in 60-day mortality was further improved from subjects of all ages in the intention-to-treat population after two doses of 15 mL of ExoFlo compared with placebo. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04493242; URL: www. CLINICALTRIALS: gov.
引用
- Lightner AL, Sengupta V, Qian S, et al. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial. Chest. 2023. PMID: 37356708. doi:10.1016/j.chest.2023.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。